US 11,655,279 B2
Method for producing active form of long-acting insulin analogue derivative using clostripain
Kyong Hoon Ahn, Seoul (KR); Seonkyeong Jeong, Gyeonggi-do (KR); and Chaeha Yoon, Gyeonggi-do (KR)
Assigned to DAEWOONG PHARMACEUTICAL CO., LTD., Gyeonggi-do (KR)
Appl. No. 17/266,580
PCT Filed Jul. 19, 2019, PCT No. PCT/KR2019/008958
§ 371(c)(1), (2) Date Feb. 6, 2021,
PCT Pub. No. WO2020/032423, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 10-2018-0092244 (KR), filed on Aug. 8, 2018.
Prior Publication US 2021/0309710 A1, Oct. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/62 (2006.01); C07K 14/76 (2006.01)
CPC C07K 14/62 (2013.01) [C07K 14/76 (2013.01); C07K 2319/31 (2013.01)] 18 Claims
1. A method for producing an active form of a long-acting insulin analogue derivative, the method comprising
a step of reacting an insulin analogue derivative with clostripain,
wherein the insulin analogue derivative comprises an insulin B-chain variant, an insulin C-chain, an insulin A-chain or variant thereof, a linker and an albumin-binding domain in that order,
wherein the insulin-B chain variant represented by the amino acid sequence of SEQ ID NO: 2, arginine (Arg) at amino acid position 22 of an insulin-B chain is substituted with lysine (Lys) in native insulin.